Peptides / Semaglutide
Semaglutide
(Wegovy, Ozempic, Rybelsus)T1glp1clinical
Biomarker Effects
Fasting glucose
↓ moderate
Improves insulin sensitivity
HbA1c
↓ small
Improves glycemic control
Fasting insulin
↓ moderate
Reduces insulin resistance
HOMA-IR
↓ moderate
Improves insulin sensitivity
Triglycerides
↓ small
Improves lipid metabolism
HDL cholesterol
↑ small
Improves lipid profile
Dosing & Pharmacokinetics
Typical Dose0.25 mg
Frequencydaily
Routeclinician-directed
Half-Life7.0 days
Safety & Evidence
Semaglutide is a GLP-1 receptor agonist approved for type 2 diabetes and obesity. Common side effects include nausea, diarrhea, and constipation. Use with caution in patients with a history of pancreatitis.
Sources
Track Semaglutide precisely in the Vivy app.
Your precision instrument awaits.
Download Vivy